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BACKGROUND
Hereditary angioedema is a life-threatening illness caused by mutations in the 
gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to over-
activation of the kallikrein–bradykinin cascade. BCX7353 is a potent oral small-
molecule inhibitor of plasma kallikrein with a pharmacokinetic and pharmaco-
dynamic profile that may help prevent angioedema attacks.
METHODS
In this international, three-part, dose-ranging, placebo-controlled trial, we evalu-
ated four doses of BCX7353 (62.5 mg, 125 mg, 250 mg, and 350 mg once daily) 
for the prevention of angioedema attacks over a 28-day period. Patients with type 
I or II hereditary angioedema with a history of at least two angioedema attacks 
per month were randomly assigned to BCX7353 or placebo. The primary efficacy 
end point was the number of confirmed angioedema attacks. Key secondary end 
points included angioedema attacks according to anatomical location and quality 
of life.
RESULTS
A total of 77 patients underwent randomization, 75 received BCX7353 or placebo, 
and 72 completed the trial. The rate of confirmed angioedema attacks was signifi-
cantly lower among patients who received BCX7353 at daily doses of 125 mg or 
more than among those who received placebo, with a 73.8% difference at 125 mg 
(P<0.001). Significant benefits with respect to quality-of-life scores were observed 
in the 125-mg and 250-mg dose groups (P<0.05). Gastrointestinal adverse events, 
predominantly of grade 1, were the most commonly reported adverse events, par-
ticularly in the two highest BCX7353 dose groups.
CONCLUSIONS
Once-daily oral administration of BCX7353 at a dose of 125 mg or more resulted 
in a significantly lower rate of attacks of hereditary angioedema than placebo. 
Mild gastrointestinal symptoms were the principal side effect. (Funded by BioCryst 
Pharmaceuticals; APeX-1 ClinicalTrials.gov number, NCT02870972.)
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Hereditary angioedema is a genetic disorder characterized by recurrent epi-sodes of swelling.1,2 Oropharyngeal swell-
ing can be life-threatening3, and attacks in other 
sites, including the limbs, genitalia, face, and 
intestines, can be painful, disabling, and disfigur-
ing and have a substantial effect on function and 
quality of life.4 Most patients with hereditary 
angioedema have mutations in the regulatory 
or coding regions of the gene that encodes C1 
inhibitor (SERPING1), which result in either a 
deficiency (type I) or dysfunction (type II) of C1 
inhibitor.5
C1 inhibitor (also called C1 esterase inhibitor) 
is a serine protease inhibitor that normally pre-
vents uncontrolled contact activation and brady-
kinin production by covalently binding to and 
inactivating plasma kallikrein.6 Increased brady-
kinin generation leads to increased vascular 
permeability and swelling.
Plasma-derived purified C1 inhibitor is ap-
proved for the prophylactic treatment of heredi-
tary angioedema through intravenous or subcu-
taneous injection. The only available effective 
drugs for oral prophylaxis against angioedema 
attacks are attenuated androgens, such as dana-
zol, and tranexamic acid. Although administra-
tion of androgens is convenient, unacceptable 
adverse effects (e.g., virilizing androgenic hor-
monal effects, hypertension, and an increased 
risk of hepatocellular adenoma or carcinoma) 
and several contraindications (e.g., in growing 
children and pregnant women) limit their clini-
cal use.7-9
BCX7353 is a potent, synthetic small molecule 
that inhibited plasma kallikrein with once-daily 
oral administration in healthy volunteers.10 In 
contrast to parenterally administered options 
under development or commercially available for 
prophylaxis against angioedema attacks, inhibi-
tion of kallikrein with an orally bioavailable 
small molecule such as BCX7353 offers the dis-
tinct advantage of oral administration.
Me thods
Trial Design
The Angioedema Prophylaxis 1 (APeX-1) trial 
was a phase 2, randomized, double-blind, pla-
cebo-controlled, parallel-group, three-part, dose-
response trial that evaluated the safety, adverse-
event profile, pharmacokinetics, pharmaco- 
dynamics,and efficacy of BCX7353 in patients 
with hereditary angioedema and C1 inhibitor 
deficiency. The trial was designed to establish 
proof of concept that a high dose of BCX7353, 
administered once daily for 28 days, was safe 
and effective in reducing the rate of angioedema 
attacks. Once proof of concept was established, 
additional doses were evaluated to characterize 
the dose response. On the basis of pharmacoki-
netic and pharmacodynamic modeling from a 
completed phase 1 study, the protocol was ini-
tially designed as a two-part trial with once-
daily doses of 350 mg, 250 mg, and 125 mg of 
BCX7353. After the trial was initiated, the proto-
col was amended to include a lower dose of 
62.5 mg of BCX7353 once daily in part 3. Eligible 
patients underwent central randomization to 
BCX7353 or placebo within each part of the trial. 
Patients participated in one trial part only. Fur-
ther details of the trial design and randomiza-
tion are provided in the protocol (available with 
the full text of this article at NEJM.org) and in 
Section S2 in the Supplementary Appendix 
(available at NEJM.org).
The trial was designed by the sponsor (Bio-
Cryst Pharmaceuticals) in collaboration with the 
first, next-to-last, and last authors. The protocol 
was approved by regulatory authorities and inde-
pendent ethics committees. All the patients pro-
vided written informed consent before the con-
duct of any trial-related procedures.
Investigators and site personnel collected data 
in collaboration with the sponsor, and the spon-
sor and PharStat (a contract research organiza-
tion paid by the sponsor) analyzed the data. All 
the authors had access to the data (nondisclosure 
agreements were in place). The first, next-to-last, 
and last authors contributed to the analysis and 
interpretation of the data. All the authors re-
viewed and approved the manuscript for publica-
tion and vouch for the completeness and accu-
racy of the data and analyses and for the 
adherence of the trial to the protocol. Technical 
support in the drafting of the manuscript, includ-
ing preparation of the first draft, was provided 
by J Anderson Solutions, funded by the sponsor.
A Quick Take 
is available at 
NEJM.org
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Patients and Patient Recruitment
Eligible male or female patients were 18 to 70 
years of age with a clinical diagnosis of type I or 
type II hereditary angioedema. Patients were 
required to have a documented rate of angio-
edema attacks of at least two attacks per month 
for 3 consecutive months within the 6 months 
before the screening visit. Patients were excluded 
if they were suspected of having C1 inhibitor 
resistance (i.e., they were having regular attacks 
despite C1 inhibitor treatment for routine pro-
phylaxis) or if they were using a C1 inhibitor, 
androgens, or tranexamic acid for prophylaxis of 
attacks within 7 days before screening. Treat-
ment of acute attacks, including the use of a C1 
inhibitor, was not excluded. Complete inclusion 
and exclusion criteria are provided in Table S3 in 
the Supplementary Appendix.
Trial Regimens
Blinded trial medication with matching placebo 
was supplied as capsules for daily oral adminis-
tration for 28 days. Patients were permitted to 
use their usual medication (including icatibant 
and intravenous and subcutaneous C1 inhibitor) 
to treat any attacks that occurred at any time 
during the trial.
Clinical Assessments
Patients were provided with paper diaries for 
daily recording of trial-regimen administration 
and angioedema attacks. If patients had an attack, 
they were to provide details of the symptoms, 
severity (using the Angioedema Activity Score),11 
triggers, and duration of the attack and medica-
tions administered to treat the attack. To assess 
the effect of the disease on the patient’s quality 
of life, the Angioedema Quality of Life Ques-
tionnaire (AE-QoL)12 was administered at the 
start and end of the intervention phase. Patients 
returned to the clinic for routine monitoring of 
vital signs, 12-lead electrocardiography, pulmo-
nary diffusion testing, physical examinations, 
laboratory assessments of serum biochemical 
and hematologic values, liver-enzyme testing, 
urinalysis, and documentation of adverse events. 
Blood samples for pharmacokinetic and pharma-
codynamic testing were obtained from patients 
before dose administration (on days 1, 14, and 29) 
and for up to 24 hours after the dose on day 14. 
Blood samples for measurement of functional 
levels of C1 inhibitor were obtained on days 1 
and 29.
Efficacy
The primary end point of the trial was the num-
ber of confirmed angioedema attacks during the 
effective dosing period (days 8 to 28, inclusive). 
All patient-reported attacks were adjudicated by 
an independent clinical end-point adjudication 
panel whose members were unaware of the trial-
group assignments. Panel membership and de-
tails regarding the adjudication process are 
provided in Section S1 in the Supplementary 
Appendix. Attacks that were confirmed by the 
adjudication panel were included in efficacy 
analyses.
Key secondary end points of the trial included 
the number of angioedema attacks categorized 
according to anatomical location and the change 
from baseline in scores on the disease-specific 
and validated AE-QoL. The AE-QoL measures 
quality of life across four domains (functioning, 
fatigue and mood, fears and shame, and food) 
and derives a total score on a scale from 0 to 100, 
with higher scores indicating greater impair-
ment. A minimal clinically important difference 
of 6 points has been described.13 Other second-
ary efficacy end points are presented in Table S7 
in the Supplementary Appendix.
Safety
The safety and adverse-event profile of BCX7353 
were assessed by means of laboratory testing 
and monitoring of patients for adverse events 
that occurred from the time of the first dose to 
the time of the last dose plus 30 days. During the 
conduct of the trial, an independent data moni-
toring committee (Table S2 in the Supplemen-
tary Appendix) provided safety oversight by re-
viewing blinded data and advising the sponsor 
on safety-related findings.
Pharmacokinetics and Pharmacodynamics
Steady-state pharmacokinetic properties of 
BCX7353 — the maximum plasma concentra-
tion (Cmax), the observed trough plasma concen-
tration at the end of the dosing interval (Ctau), 
the time at which Cmax occurred, and the area 
under the plasma concentration–time curve dur-
ing the dosing interval (AUCtau) — were addi-
tional secondary end points, as was the ex vivo 
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kallikrein inhibition activity of BCX7353 (ana-
lyzed as described previously10).
Statistical Analysis
In part 1 of the trial, we calculated that a sample 
of 18 patients per group would provide a power 
of 93% to detect a difference in the attack rate of 
0.5 attacks per week between the 350-mg BCX7353 
group and the placebo group at an alpha level of 
0.05, assuming a mean baseline rate of 1 attack 
per week. The primary efficacy end point of the 
trial was the number of confirmed angioedema 
attacks in the intention-to-treat and per-protocol 
populations. Population definitions and num-
bers of patients included in each population are 
summarized in Section S4 in the Supplementary 
Appendix. The number of angioedema attacks 
was analyzed according to trial group with the 
use of appropriate descriptive statistics for the 
weekly attack rate, change and percentage change 
from baseline in attack rate, proportion of pa-
tients with no attacks, and number and percent 
of attack-free days. Efficacy analyses were con-
ducted for angioedema attacks reported during 
the entire dosing interval (days 1 to 28, inclusive) 
and during the effective dosing period in which 
BCX7353 levels were at a steady state (days 8 to 
28, inclusive).
Between-group comparisons (BCX7353 vs. pla-
cebo) for the weekly attack rate were performed 
with the use of an analysis-of-covariance model. 
The adjusted qualifying attack rate was included 
as a covariate in the model. The least-squares 
mean for each trial group and the relative differ-
ence and associated 95% confidence intervals in 
attack rate between the placebo group and each 
BCX7353 dose group were calculated.
Data for the primary end point are shown for 
the effective dosing period in the intention-to-
treat population, since this would best assess 
the effectiveness of the trial medication after 
steady-state levels had been achieved in this 
small, phase 2 trial. Data are also presented for 
the per-protocol population and during the en-
tire dosing period. The primary efficacy analysis 
was conducted without imputation for missing 
data (Tables S5 and S6 in the Supplementary Ap-
pendix).
Analyses of the primary end point of the 
number of confirmed attacks, followed by the 
secondary end point of AE-QoL scores, were per-
formed with the use of post hoc hierarchical 
testing to preserve the prespecified level of sig-
nificance of 0.05. Safety analyses were based on 
the safety population and included all randomly 
assigned patients who received a dose of a trial 
regimen. All statistical analyses were performed 
with the use of SAS software (version 9.3).
R esult s
Patients
The trial was initiated in August 2016, and the 
last patient observation occurred in August 2017. 
A total of 86 patients were screened from 26 sites 
across Europe, Canada, and Australia. Of the 77 
patients who underwent randomization, 2 never 
received a trial regimen or entered any diary data 
and 3 discontinued the trial regimen owing to 
an adverse event or laboratory abnormality. De-
tails regarding disposition of the patients and 
discontinuation are presented in Figure S2 and 
Table S4, respectively, in the Supplementary Ap-
pendix.
The trial groups were generally balanced with 
respect to age and qualifying attack rate, although 
the proportion of women was not evenly distrib-
uted across groups, and patients in the 350-mg 
dose group had a higher rate of previous andro-
gen use than the other groups (Table 1). Baseline 
C1 inhibitor levels were low, with median values 
ranging from 19% to 34% of normal values. 
Sequential enrollment into parts 1, 2, and 3 may 
have contributed to the differences in demo-
graphic and clinical characteristics that were ob-
served among the trial groups.
Efficacy Results
Primary End Point
The primary efficacy end point was the number 
of confirmed angioedema attacks. Significant 
and clinically meaningful differences in the rate 
of attacks were observed between patients who 
received BCX7353 at doses of 125 mg or more 
once daily and those who received placebo (Ta-
ble 2). The least-squares mean rate of attacks 
among patients who received placebo (pooled 
across all three parts of the trial) was 0.95 per 
week, and the least-squares mean percent differ-
ences in the confirmed rate of attacks per week 
according to BCX7353 dose group were as follows: 
350 mg, −45.5% (P = 0.006); 250 mg, −44.6% 
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(P = 0.01); 125 mg, −73.8% (P<0.001); and 62.5 mg, 
−10.5% (P = 0.64).
When attack rates were analyzed according to 
anatomical location, a differential response was 
observed for peripheral attacks as compared with 
abdominal attacks, particularly at the 250-mg 
and 350-mg doses of BCX7353 (Table 2). Al-
though the rate of peripheral attacks was lower 
with BCX7353 than with placebo at all doses of 
125 mg or more, the rate of abdominal attacks 
was lower with BCX7353 than with placebo at 
the 125-mg dose only.
Secondary End Points
The percent of attack-free days and the proportion 
of patients who were attack-free were higher with 
BCX7353 at doses of 125 mg or more than with 
placebo (Table 2). An important secondary end 
point in the trial was quality of life as measured 
by the AE-QoL. The least-squares mean change 
from baseline in the AE-QoL total score was −29.0 
in the 125-mg dose group, as compared with 
−4.5 in the placebo group (difference, −24.5; 
P<0.001), indicating a significant benefit with 
the 125-mg dose. There were also significant dif-
ferences favoring the 125-mg dose across three 
of the four domains of the AE-QoL (P≤0.006 vs. 
placebo) (Fig. 1). A significant difference between 
the 250-mg dose group and the placebo group was 
observed for the functioning domain (P = 0.02), 
in favor of the 250-mg dose. Results for other 
secondary end points, including the rate of at-
tacks resulting in treatment and the overall sever-
ity of illness, support the efficacy of BCX7353 at 
doses of 125 mg or more (Table S7 in the Sup-
plementary Appendix). None of the patients dis-
continued the trial medication owing to lack of 
efficacy.
Pharmacokinetics and Pharmacodynamics
After administration of multiple daily doses of 
BCX7353, the Cmax was reached at a median of 3 to 
4 hours after dosing (Fig. 2A). At doses of 125 mg 
or more, geometric mean plasma trough concen-
trations (Ctau) were generally maintained above 
the minimum target concentration range (ap-
proximately 4 times the half-maximal effective 
concentration [EC50]) throughout the dosing inter-
val. There was a greater-than-dose-proportional 
increase in exposure (AUCtau and Cmax) across the 
dose range of 62.5 mg to 350 mg, with an in-
crease in exposure of approximately 11 times 
with an increase in dose of 4.6 times (Table S8 
in the Supplementary Appendix). A dose-depen-
dent inhibition of kallikrein was observed with 
BCX7353 treatment across the dose range (Fig. 2B), 
Characteristic BCX7353
Placebo 
(N = 23)
62.5 mg 
(N = 7)
125 mg 
(N = 14)
250 mg 
(N = 15)
350 mg 
(N = 18)
Age — yr 38.9±16.6 48.1±12.6 39.5±13.9 43.8±11.6 46.6±10.9
Female sex — no. (%) 6 (86) 10 (71) 7 (47) 11 (61) 13 (57)
Race — no. (%)†
White 7 (100) 14 (100) 12 (80) 15 (83) 21 (91)
Asian 0 0 1 (7) 1 (6) 0
Other 0 0 2 (13) 2 (11) 2 (9)
Previous androgen use — no. (%) 3 (43) 4 (29) 8 (53) 15 (83) 13 (57)
Angioedema attacks/wk‡ 1.15±0.52 0.99±0.52 0.93±0.45 0.90±0.44 1.03±0.57
Median C1 inhibitor function (IQR) — %  
of normal value
11 (7–47) 15 (11–35) 15 (6–28) 19 (5–28) 10 (4–37)
Alanine aminotransferase — U/liter 18.4±6.6 22.0±9.5 31.0±20.5 42.5±44.1 29.0±13.0
*  Plus–minus values are means ±SD. The intention-to-treat population included all the patients who underwent random-
ization. IQR denotes interquartile range.
†  Race was reported by the patient.
‡  The baseline attack rate was based on patient-reported attacks over a 3-month period.
Table 1. Baseline Characteristics of the Patients (Intention-to-Treat Population).*
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a finding consistent with the exposure data. The 
drug effect on kallikrein inhibition was corre-
lated with exposure (r2 = 0.75) (data not shown).
Safety
Three patients who received BCX7353 at a dose 
of 350 mg discontinued the trial regimen owing 
to adverse events (Table 3). A total of 67% of all 
adverse events were mild in severity (grade 1). 
Analysis of the adverse-event profile identified a 
dose-related increase in the incidence of gastro-
intestinal events. Gastrointestinal events were 
most commonly reported in the 350-mg dose 
group (44%) and 250-mg dose group (50%), with 
considerably fewer in the 125-mg dose group 
(29%) and 62.5-mg dose group (14%); the inci-
dence in the 62.5-mg dose group was similar to 
that in the placebo group (18%). Gastrointesti-
nal events were generally mild (grade 1, 75% of 
treated patients with such events) to moderate 
(grade 2, 20%) in severity, although one patient 
in the 350-mg dose group had severe (grade 3) 
abdominal pain that led to discontinuation of 
the trial regimen (Table 3). Only mild (grade 1) 
gastrointestinal events occurred in the 125-mg 
and 62.5-mg dose groups.
A total of three patients who received BCX7353 
had mild (grade 1) or moderate (grade 2) liver-
related adverse events (one patient in the 250-mg 
dose group and one in the 350-mg dose group 
had grade 1 events, and one patient in the 350-mg 
dose group had a grade 2 event). Two additional 
patients in the 350-mg dose group had a grade 3 
or grade 4 liver-enzyme abnormality: one patient 
had a grade 3 elevation in the γ-glutamyltransferase 
level (3.4 times the upper limit of the normal 
range), and the other patient had a grade 3 eleva-
tion in the alanine aminotransferase level (3.9 
times the upper limit of the normal range) and 
a grade 4 elevation in the γ-glutamyltransferase 
Figure 1. Change from Baseline at Day 29 in Scores on the Angioedema Quality of Life Questionnaire (AE-QoL)  
in the Intention-to-Treat Population.
The least-squares mean change from baseline for each trial group is shown. An analysis-of-covariance model included 
terms of trial regimen and adjusted qualifying attack rate. The intention-to-treat population included all the patients 
who underwent randomization. The AE-QoL total score and scores for each of the four domains range from 0 to 100, 
with higher scores indicating greater impairment. The horizontal line represents the minimal clinically important 
difference (MCID) for the total score, a 6-point reduction.13 There were significant differences between patients who 
received BCX7353 at a dose of 125 mg daily and those who received placebo in the total score (difference in least-
squares mean change from baseline, −24.5 points; P<0.001) and across three of the four domains: functioning 
(−26.7 points, P = 0.002), fatigue and mood (−11.6 points, P = 0.054), fears and shame (−33.8 points, P<0.001), and 
food (−24.4 points, P = 0.006). There was also a significant difference between the 250-mg dose group and the pla-
cebo group in the functioning score (difference, −20.3 points; P = 0.02). No other differences (BCX7353 vs. placebo) 
were significant. T bars indicate standard errors.
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level (10.7 times the upper limit of the normal 
range). Both patients had elevated liver-enzyme 
levels at baseline.
All five of these patients had extensive histo-
ries of previous androgen use. These patients’ 
laboratory values returned to normal or baseline 
without intervention once dosing was completed. 
No liver-related adverse events or grade 3 or 4 
liver-enzyme abnormalities were observed at the 
125-mg or 62.5-mg doses.
Discussion
The APeX-1 trial showed that BCX7353 at doses of 
125 mg or more administered orally once daily 
resulted in markedly lower rates of angioedema 
attacks than placebo. An apparent U-shaped dose 
response was observed in the primary end point, 
with the highest treatment effect observed at the 
125-mg dose: the attack rate was 73.8% lower 
than with placebo, and 43% of patients were 
attack-free.
The data suggest that the efficacy of the 
BCX7353 doses of 250 mg and 350 mg was prob-
ably masked by gastrointestinal adverse events 
that may have been misattributed as early symp-
toms of abdominal angioedema attacks. Only 
the 125-mg dose group had a lower rate of ab-
dominal attacks than the placebo group, where-
as all groups that received BCX7353 at doses of 
125 mg or more had lower rates of peripheral 
attacks than the placebo group (difference, 68% 
Figure 2. Dose of BCX7353, Concentration–Time Profile 
at Steady State, and Plasma Kallikrein Inhibition.
On day 14, serial blood samples were drawn for pharma-
cokinetic analysis (Panel A) before dose administration 
and at the following time points: 1, 2, 3, 4, 5, 6, 8, and 
24 hours after dose administration. For the 24-hour post-
dose samples, patients returned to the clinic and had 
the blood sample drawn before dose administration on 
day 15. On day 29, a trough pharmacokinetic blood sam-
ple was drawn. However, if serial pharmacokinetic samples 
could not be obtained on day 14, steady-state serial phar-
macokinetic samples were obtained on day 28, with a 
24-hour pharmacokinetic sample drawn at the sched-
uled visit on day 29. The plasma samples for determi-
nation of BCX7353 concentrations were analyzed with 
the use of a validated liquid chromatography–mass 
spectrometry assay. In this trial, none of the patients 
who received 62.5 mg of BCX7353 met or exceeded the 
target of 4 times the EC50 across the 24-hour dosing in-
terval, whereas 9 of 14 patients who received 125 mg 
met or exceeded the target, and all the patients who re-
ceived 250 mg or 350 mg exceeded the target concen-
tration. Kallikrein inhibition (Panel B) was measured in 
an ex vivo fluorogenic assay.10 The assay uses ellagic acid 
to activate the contact pathway and convert pre kallikrein 
to kallikrein. A fluorogenic substrate that is specific for 
the enzyme (N-carbobenzyloxy-phenylalanine-arginine-
7-amino-4-methylcoumarin) was used to measure its 
amidolytic activity. Owing to the dilution in the sample 
preparation for the assay, the BCX7353 concentration in 
the ex vivo assay represents one quarter of the corre-
sponding in vivo plasma concentration. The results of 
kallikrein activity were expressed as percent inhibition 
as compared with the activity present in the predose 
plasma sample on day 1. At doses of 250 mg or 350 mg 
of BCX7353, maximum kallikrein inhibition was approx-
imately 90%, and inhibition of more than 75% was main-
tained throughout the 24-hour dosing period. Maximum 
kallikrein inhibition with 125 mg of BCX7353 was approx-
imately 60%, with 45% inhibition at 24 hours, whereas 
at a dose of 62.5 mg, maximum inhibition was approxi-
mately 30%, with 8% kallikrein inhibition at 24 hours.
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Event BCX7353 Placebo (N = 22)
62.5 mg 
(N = 7)
125 mg 
(N = 14)
250 mg 
(N = 14)
350 mg 
(N = 18)
number of patients (percent)
Any adverse event 4 (57) 7 (50) 11 (79) 14 (78) 15 (68)
Any serious adverse event 0 0 1 (7)† 0 0
Grade 3 adverse event considered to be related to the trial regimen‡ 0 0 0 1 (6) 0
Adverse event leading to discontinuation of the trial regimen 0 0 0 3 (17)§ 0
Most commonly reported adverse events¶
Any gastrointestinal adverse event 1 (14) 4 (29) 7 (50) 8 (44)  4 (18)
Abdominal pain‖ 1 (14) 3 (21) 2 (14) 3 (17) 0
Diarrhea 0 0 2 (14) 4 (22) 2 (9)
Flatulence 0 0 0 2 (11) 0
Nausea 0 0 3 (21) 3 (17) 0
Vomiting 0 0 0 2 (11) 0
Fatigue 1 (14) 0 0 2 (11) 1 (5)
Nasopharyngitis 2 (29) 0 1 (7) 5 (28)  6 (27)
Liver-related event** 0 0 1 (7) 2 (11) 0
Headache 2 (29) 2 (14) 1 (7) 1 (6)  4 (18)
*  The safety population included all randomly assigned patients who received a dose of a trial regimen. Shown are events that started after 
the date and time of the first dose to the last dose plus 30 days. Adverse events were graded according to the Division of Microbiology 
and Infectious Diseases Adult Toxicity Table (November 2007): grade 1 indicated mild, grade 2 moderate, grade 3 severe, and grade 4 life-
threatening. No patient had a grade 4 adverse event.
†  A grade 2 gastrointestinal infection was considered to be unrelated to the trial regimen. Abdominal symptoms of gastrointestinal infection 
were similar to those in several previous (non–hereditary angioedema attack) episodes occurring during the previous 3 years that resulted in 
severe vomiting and diarrhea and an overnight hospitalization for intravenous fluids and antiemetics.
‡  In addition to the adverse events that were considered by the investigator to be related to the trial regimen, two patients in the 350-mg dose 
group had grade 3 adverse events that were considered to be unrelated to the trial regimen. One patient had a persistent grade 3 elevation 
in the alanine aminotransferase (ALT) level that was present at baseline, before the first dose of the trial regimen. One patient had a grade 
3 gastrointestinal infection 1 week after completion of the last dose of the trial regimen.
§  Reasons for discontinuation were grade 1 liver disorder (in one patient), grade 3 elevation in the ALT level (in one  patient), and grade 3 
abdominal pain and grade 2 vomiting (in one patient). The liver disorder was considered to be probably related to the trial regimen and 
occurred after a case of grade 1 gastroenteritis; the patient discontinued the trial regimen on day 18. Increases in levels of ALT (1.9 times 
the upper limit of the normal range [ULN] [grade 1]), γ-glutamyltransferase (5.4 times the ULN [grade 3]), and alkaline phosphatase (1.6 
times the ULN [grade 1]) were  observed, although levels of aspartate aminotransferase and bilirubin remained within the normal range. The 
grade 3  elevation in the ALT level was considered unlikely to be related to the trial regimen, and although the patient’s ALT level was less 
than 2 times the ULN at screening (44 IU per liter, or 1.3 times the ULN [grade 1]) (i.e., the patient met the inclusion criteria), the patient 
entered the trial with an elevated ALT level (123 IU per liter, or 3.7 times the ULN [grade 3]) at baseline that remained at grade 2 or higher 
during the trial; the patient discontinued the trial regimen on day 23. The patient had received danazol (100 mg) before trial entry. The ab-
dominal pain and vomiting were considered to be possibly related to the trial regimen and occurred two times before the third episode that 
resulted in discontinuation of the trial regimen on day 12.
¶  Shown are adverse events that occurred in at least 10% of the patients enrolled in any trial group. Events are listed according to preferred 
term.
‖  Abdominal pain included the following reported terms: abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort, 
and dyspepsia.
**  Liver-related events were reported as liver disorder, elevation in the ALT level, and abnormal liver-function test. The elevation in the ALT 
level (in the 350-mg dose group) was mild in severity and was considered to be possibly related to the trial regimen. The ALT level increased 
from a normal baseline value (29 IU per liter) to grade 1 at day 29 (51 IU per liter) and at follow-up (86 IU per liter). The ALT level was 
within the normal range at day 65. The abnormal liver-function test (in the 250-mg dose group) was mild in severity, was considered to  
be possibly related to the trial regimen, and represented a 1-grade shift in the ALT level (grade 2 at baseline to grade 3 from day 7 through 
the end of the intervention). At follow-up on day 43, the ALT level was near baseline (107 IU per liter); approximately 1 month later, the 
ALT level had decreased to within the normal range. The liver disorder (in the 350-mg dose group) resulted in discontinuation of the trial 
regimen (discussed above).
Table 3. Summary of Adverse Events (Safety Population).*
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to 82%). Gastrointestinal adverse events were 
more common at the doses of 250 mg and 350 mg 
than at lower doses, and a small number of liver 
abnormalities were observed at the highest doses 
in patients with extensive previous use of andro-
gens. The side-effect profile in this trial was 
consistent with a trial involving healthy volun-
teers, in which gastrointestinal adverse events were 
more commonly reported in higher BCX7353 dose 
groups.10
The effectiveness of BCX7353 was further sup-
ported by secondary efficacy end points involv-
ing a post hoc hierarchical analysis, with sub-
stantial improvements observed in patients’ 
quality of life at the 125-mg dose level, although 
post hoc P values should be interpreted with 
some caution. The mean improvement (change 
from baseline) in the AE-QoL total score was 
greater than 4 times the minimal clinically im-
portant difference of 6 points.13 In addition, pa-
tients who received BXC7353 at doses of 125 mg 
or more had lower rates of attacks resulting in 
treatment and a lower overall severity of illness 
than those who received placebo.
An analysis of attack rates according to dose 
and exposure in this trial supports a hypothesis 
that drug exposures that are maintained above a 
threshold concentration at least 4 times the EC50 
correlate with clinically meaningful reductions in 
attack rates. In this trial, only doses of 125 mg 
or more provided trough concentrations at least 
4.0 times the EC50 with corresponding signifi-
cant differences in the attack rate as compared 
with placebo. A 62.5-mg dose provided a mean 
Ctau of 1.8 times the EC50, with no significant 
difference in attack rate as compared with pla-
cebo (P = 0.64), whereas a 125-mg dose provided 
a mean Ctau of 5.0 times the EC50, with a corre-
sponding difference in the attack rate of 73.8% 
as compared with placebo (P<0.001).
These data are consistent with exposure- 
response results from a phase 3 trial of a subcu-
taneous preparation of C1 inhibitor (Clinical 
Study for Optimal Management of Preventing 
Angioedema with Low-Volume Subcutaneous C1-
Inhibitor Replacement Therapy [COMPACT]).14 
In that trial, a clinically meaningful reduction in 
the frequency of attacks correlated with a trough 
plasma level of C1 inhibitor equal to 5.3 to 6.3 
times the EC50 of C1 inhibitor on plasma kalli-
krein, which was determined by the same assay 
used to estimate the EC50 of BCX7353. In our 
trial, trough concentrations that were achieved 
at the 250-mg and 350-mg doses were 14 to 20 
times the EC50, which suggests that these doses 
are in excess of those required to achieve clini-
cally meaningful reductions in the attack rate.
In a phase 3 study (OPuS-2) of avoralstat, a 
first-generation oral kallikrein inhibitor admin-
istered three times a day, efficacy in preventing 
angioedema attacks in patients with hereditary 
angioedema was not shown.15 As compared with 
BCX7353, avoralstat had inferior pharmacokinetic 
properties, with low oral bioavailability, a short 
half-life, and a food effect on plasma exposure. 
Reported plasma concentrations of avoralstat 
from the OPuS-2 study were highly variable, with 
many time points having drug levels below the 
target therapeutic concentration of 4 times the 
EC50 for the drug. The results of the OPuS-2 trial 
further support the hypothesis that maintenance 
of drug levels above a threshold level for plasma 
kallikrein suppression is important in reducing 
the frequency of angioedema attacks.
In conclusion, this trial showed both proof 
of concept and dose response of orally admin-
istered BCX7353 in the prevention of angio-
edema attacks through short-lasting kallikrein 
inhibition. Longer studies will need to be per-
formed to assess the safety profile of long-term 
dosing.
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